Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of pyridoxamine (RS8001) for PMS and PMDD
jRCT2021200026Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pyridorin in premenstrual syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Luteal phase DRSP negative mood score (core PMDD symptoms). Started Sep 2021; status: active, not recruiting.
02
Drugs
pyridorin
03
Conditions
premenstrual syndrome (PMS)Premenstrual Dysphoric Disorder (PMDD)
Beyond the preview
Go deeper on jRCT2021200026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021200026.